Skip to content

The Effect of a Patient Decision Aids for Breast Cancer Screening

Patient Decision Aids for Women Facing the Decision of Breast Cancer Screening in the Public Health Sector

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04948983
Enrollment
3269
Registered
2021-07-02
Start date
2021-07-01
Completion date
2022-10-31
Last updated
2022-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Tumor, Mammary Cancer, Mammary Tumor

Keywords

Breast Cancer, Decision aid, Decision making process, Mammography, Breast Cancer Screening

Brief summary

Breast cancer is one of the most common cancers in Chile. National efforts focus on early detection, offering universal access to breast cancer screening through mammography to women at risk age. However, 30% of women do not undertake the exam due to a lack of knowledge and anxiety when facing the decision. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres. A total of 3,269 women aged 50 to 69 years old are invited to join the study. The intervention group accesses a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group accesses a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate are measured. Multiple lineal regression analysis will be conducted.

Detailed description

There is an alarming rise of breast cancer in developing countries, where early detection is rare and the late findings build up an important mortality rate. In Chile, the mortality rate is 15,5 per 100.000 women, where breast cancer is the first death caused by tumors. Governmental efforts had focused on increase an opportune detection and had offered universal and guaranteed access to breast cancer screening to women in at-risk age (50 to 59 years old). Still, about 30% of the women of at-risk age choose to not do the mammogram. Anxiety and lack of awareness are the principal reasons associated with the decision of rejecting or postponing the exam. Women would have trouble in making an informed decision about the breast cancer exam, resulting in possible negatives consequences for their wellbeing. Considering that the health-related decision-making process depends importantly on the personal balance of risk and benefits related to the decision, it is imperative to explore strategies that support women in the decision-making progress for breast cancer screening. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres; 4) A two-arm randomized control trial will be conducted with a total of 3,269 women aged 50 to 69 years old in ten primary care centres in Chile. The intervention group will access a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group will access a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups will complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate will be measure. Multiple lineal regression analysis will be conducted.

Interventions

OTHERDecision aid (DA) for breast cancer screening

The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?

OTHERStandarised information for breast cancer screening

Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)

Sponsors

Comisión Nacional de Investigación Científica y Tecnológica
CollaboratorOTHER_GOV
Pontificia Universidad Catolica de Chile
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

The intervention group will access a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group will access a webpage, answers a set of questionnaires at baseline, and then receive standardised information given by the healthcare system. Both groups will complete the questionnaires two weeks later.

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 69 Years
Healthy volunteers
Yes

Inclusion criteria

* Women from 50 to 69 years old * Attend the primary care centres * Fluent in Spanish

Exclusion criteria

* Women with a personal history of breast cancer * Have a current mammogram (as recommended by the Chilean Ministry of Health) * Not having the capacity to consent.

Design outcomes

Primary

MeasureTime frameDescription
Informed choice for breast cancer screeningChange from baseline informed choice at two weeksAn adapted and validated version of the informed choice questionnaire will be used: this is a five-item questionnaire to measure informed choice (Bravo P, Dois A, Fernández-González L, Hernández-Leal MJ, Villarroel L. \[Validation of the Informed Choice instrument for Chilean women facing a mammography decision in primary care\]. Aten Primaria. 2021 Mar;53(3):101943. doi: 10.1016/j.aprim.2020.08.005. Epub 2021 Feb 13. Spanish. PubMed ID: 33592532). Minimum value= 5 Maximum value= 25

Secondary

MeasureTime frameDescription
Decisional conflictChange from baseline decisional conflict at two weeksDecisional conflict scale with 16 items that measure uncertainty in the decision making process. Minimum value= 16 Maximum value= 80
Depression, anxiety and stressChange from baseline drepression, anxiety and stress at two weeksThis will be measured with the DASS-21 Scale, a self-reported 21-item that captures depression, anxiety and stress during the last week. Minimum value= 21 Maximum value= 84
Satisfaction with the decisionChange from baseline satisfaction with the decision at two weeksThis is a two-item self-reported satisfaction questionnaire related to breast cancer screening. Minimum value= 0 Maximum value= 1
Number of participants who undertake a mammographyAt 6 monthsThis will be the number of women who decided to undertake the mammography. This outcome will be obtained from the clinical record of each participant six months after baseline questionnaires. Minimum value= 0 Maximum value= 1

Countries

Chile

Contacts

Primary ContactPaulina Bravo, PhD
pbbravo@uc.cl(56-2) 2354 5838
Backup ContactAlejandra Martinez, MSc
alejandra.martinez@uc.cl+56940742491

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026